Marie-Francoise Heymann
Overview
Explore the profile of Marie-Francoise Heymann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
1944
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Munoz-Garcia J, Vargas-Franco J, Schiavone K, Keatinge M, Young R, Amiaud J, et al.
Theranostics
. 2025 Mar;
15(7):3185-3202.
PMID: 40083929
During development, the contribution of IL34, a ligand of macrophage colony stimulating factor receptor (MCSFR), has not been fully defined. Together with its twin cytokine MCSF, they display an essential...
2.
Heymann M
Ann Pathol
. 2024 Oct;
44(6):453-460.
PMID: 39389897
Extraosseous calcifications correspond to ubiquitous deposits of intra-tissue calcium salts leading to dysfunction of the affected tissue or organ. There are two types: metastatic calcifications and dystrophic calcifications. Their formation...
3.
Jubelin C, Munoz-Garcia J, Ollivier E, Cochonneau D, Vallette F, Heymann M, et al.
Biochim Biophys Acta Mol Cell Res
. 2024 Jan;
1871(3):119660.
PMID: 38216092
Dormancy is a potential way for tumors to develop drug resistance and escape treatment. However, the mechanisms involved in cancer dormancy remain poorly understood. This is mainly because there is...
4.
Panez-Toro I, Heymann D, Gouin F, Amiaud J, Heymann M, Cordova L
Front Immunol
. 2023 Dec;
14:1310262.
PMID: 38106424
Classically, particle-induced periprosthetic osteolysis at the implant-bone interface has explained the aseptic loosening of joint replacement. This response is preceded by triggering both the innate and acquired immune response with...
5.
Jubelin C, Munoz-Garcia J, Cochonneau D, Ollivier E, Vallette F, Heymann M, et al.
Front Bioeng Biotechnol
. 2023 Oct;
11:1260049.
PMID: 37869710
The mechanisms involved in cancer initiation, progression, drug resistance, and disease recurrence are traditionally investigated through adherent monolayer (2D) cell models. However, solid malignant tumor growth is characterized by progression...
6.
Panez-Toro I, Munoz-Garcia J, Vargas-Franco J, Renodon-Corniere A, Heymann M, Lezot F, et al.
Curr Osteoporos Rep
. 2023 Jun;
21(4):330-343.
PMID: 37329384
Purpose Of Review: This article gives a brief overview of the most recent developments in osteosarcoma treatment, including targeting of signaling pathways, immune checkpoint inhibitors, drug delivery strategies as single...
7.
Jubelin C, Munoz-Garcia J, Griscom L, Cochonneau D, Ollivier E, Heymann M, et al.
Cell Biosci
. 2022 Sep;
12(1):155.
PMID: 36089610
Cancer is a multifactorial disease that is responsible for 10 million deaths per year. The intra- and inter-heterogeneity of malignant tumors make it difficult to develop single targeted approaches. Similarly,...
8.
Heymann C, Bobin-Dubigeon C, Munoz-Garcia J, Cochonneau D, Ollivier E, Heymann M, et al.
J Bone Oncol
. 2022 Aug;
36:100451.
PMID: 35990515
Osteosarcoma (OS) is a rare malignant primary bone tumours characterized by a high genetic and cell composition heterogeneity. Unfortunately, despite the use of drug combinations and the recent development of...
9.
Jubelin C, Munoz-Garcia J, Cochonneau D, Moranton E, Heymann M, Heymann D
Cancer Drug Resist
. 2022 May;
5(1):184-198.
PMID: 35582537
Sarcomas are a large family of cancers originating in the mesenchyme. Composed of more than 100 histological subtypes, soft tissue and bone sarcomas remain clinically challenging, particularly in children and...
10.
Munoz-Garcia J, William Vargas-Franco J, Brounais-Le Royer B, Cochonneau D, Amiaud J, Heymann M, et al.
Cancers (Basel)
. 2022 Apr;
14(7).
PMID: 35406536
Current treatments for osteosarcoma, combining conventional polychemotherapy and surgery, make it possible to attain a five-year survival rate of 70% in affected individuals. The presence of chemoresistance and metastases significantly...